Ophthalmically acceptable compositions used in arresting the development
of cataract, presbyopia, macular degeneration and other retinopathies,
glaucoma, uveitis and various corneal disorders are disclosed. The
compositions are also useful as a prophylactic treatment to prevent or
delay development of age-related ocular disorders, which include
cataracts, presbyopia, glaucoma and macular degeneration. The
compositions comprise a pharmaceutically acceptable carrier or diluent
and at least one compound having the formula: 1
where R.sub.1 and R.sub.2 are, independently, H or C.sub.1 to C.sub.3
alkyl;
R.sub.3 and R.sub.4 are, independently C.sub.1 to C.sub.3 alkyl; and
where R.sub.1 and R.sub.2, taken together, or R.sub.3 and R.sub.4, taken
together, or both may be cycloalkyl;
R.sub.5 is H, OH, or C.sub.1 to C.sub.6 alkyl;
R.sub.6 is or C.sub.1 to C.sub.6 alkyl, alkenyl, alkynyl, or substituted
alkyl or alkenyl;
R.sub.7 is C.sub.1 to C.sub.6 alkyl, alkenyl, alkynyl, or substituted
alkyl or alkenyl or where R.sub.6 and R.sub.7, or R.sub.5, R.sub.6 and
R.sub.7, taken together, form a carbocycle or heterocycle having from 3
to 7 atoms in the ring.
